3/12
10:04 am
cdtx
Cidara Therapeutics, Inc. (NASDAQ: CDTX) is now covered by analysts at Citigroup Inc.. They set an "outperform" rating on the stock.
Low
Report
Cidara Therapeutics, Inc. (NASDAQ: CDTX) is now covered by analysts at Citigroup Inc.. They set an "outperform" rating on the stock.
3/12
10:03 am
cdtx
Cidara Therapeutics, Inc. (NASDAQ: CDTX) was given a new $46.00 price target on by analysts at JMP Securities.
Low
Report
Cidara Therapeutics, Inc. (NASDAQ: CDTX) was given a new $46.00 price target on by analysts at JMP Securities.
3/12
07:22 am
cdtx
Cidara Therapeutics, Inc. (NASDAQ: CDTX) is now covered by analysts at Citizens Jmp. They set an "outperform" rating and a $46.00 price target on the stock.
High
Report
Cidara Therapeutics, Inc. (NASDAQ: CDTX) is now covered by analysts at Citizens Jmp. They set an "outperform" rating and a $46.00 price target on the stock.
3/10
08:03 am
cdtx
Cidara Therapeutics, Inc. (NASDAQ: CDTX) had its price target raised by analysts at HC Wainwright from $24.00 to $35.00. They now have a "buy" rating on the stock.
Medium
Report
Cidara Therapeutics, Inc. (NASDAQ: CDTX) had its price target raised by analysts at HC Wainwright from $24.00 to $35.00. They now have a "buy" rating on the stock.
3/7
08:12 am
cdtx
Cidara Therapeutics, Inc. (NASDAQ: CDTX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $35.00 price target on the stock.
Low
Report
Cidara Therapeutics, Inc. (NASDAQ: CDTX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $35.00 price target on the stock.
3/6
05:21 pm
cdtx
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results [Yahoo! Finance]
Low
Report
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results [Yahoo! Finance]
3/6
04:35 pm
cdtx
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Low
Report
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
2/18
04:15 pm
cdtx
Cidara Therapeutics Announces Appointment of Frank Karbe as Chief Financial Officer
Low
Report
Cidara Therapeutics Announces Appointment of Frank Karbe as Chief Financial Officer
2/6
06:47 am
cdtx
Cidara Therapeutics, Inc. (NASDAQ: CDTX) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.
Medium
Report
Cidara Therapeutics, Inc. (NASDAQ: CDTX) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.
1/30
04:40 pm
cdtx
Cidara Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference [Yahoo! Finance]
Low
Report
Cidara Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference [Yahoo! Finance]
1/30
04:05 pm
cdtx
Cidara Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
Low
Report
Cidara Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
1/27
09:34 am
cdtx
Cidara Therapeutics, Inc. (NASDAQ: CDTX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Medium
Report
Cidara Therapeutics, Inc. (NASDAQ: CDTX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
1/21
09:38 am
cdtx
As H5N1 Is Detected In San Francisco, A Panel Discusses Next Steps [Forbes]
Low
Report
As H5N1 Is Detected In San Francisco, A Panel Discusses Next Steps [Forbes]
12/23
04:59 pm
cdtx
Cidara Therapeutics files to sell 7.04M shares of common stocks by selling shareholders [Seeking Alpha]
Medium
Report
Cidara Therapeutics files to sell 7.04M shares of common stocks by selling shareholders [Seeking Alpha]
12/13
07:49 am
cdtx
Cidara Therapeutics, Inc. (NASDAQ: CDTX) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $34.00 price target on the stock.
Medium
Report
Cidara Therapeutics, Inc. (NASDAQ: CDTX) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $34.00 price target on the stock.